Back to search results

NANOVAE for Knee Osteoarthritis

This study is testing NANOVAE, a product made from human amniotic fluid, for people with knee osteoarthritis (KOA). NANOVAE contains natural components like growth factors and tiny particles (nanoparticles) that may help repair cartilage and reduce inflammation in the knee. The study aims to see if NANOVAE is safe and if it helps improve KOA. You may be able to join if you are between 21 and 75 years old and have KOA. The main goal is to track any side effects from NANOVAE. This study is currently recruiting 24 participants.

Study design
This study will involve 24 participants. It includes an open-label phase and a randomized, double-blinded, placebo-controlled phase where some participants will receive NANOVAE and others will receive a saline (saltwater) placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for 30 days after receiving the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06606561

NANOVAE to Treat Knee Osteoarthritis (KOA)

Not Yet Recruiting
PHASE1Ages 21–75InterventionalTreatment
Nova Vita Laboratory
~24 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)0.9% Sodium Chloride Injection, USP

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of NANOVAE administered intraarticular in subjects
Measured over 30 Days

Conditions

Knee Osteoarthritis

Explore related trials

Osteoarthritis of knee

NCT06606561

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Bluetail Medical Group

    Chesterfield, Missouristudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

David Crane, MD
[email protected]
(636) 778-2900
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of NANOVAE administered intraarticular in subjects30 Days

    To demonstrate the safety of NANOVAE administered intraarticular in subjects with KOA by measuring incidence of any of the following treatment-emergent adverse events (TE-AEs) and treatment-emergent serious adverse events (TE-SAEs) within the first 30 days of injection: * Occurrence of adverse events related to the therapy within 30 days of NANOVAE treatment. * Life-threatening event (e.g., stroke or non-fatal pulmonary embolism). * Event resulting in persistent or significant disability/incapacity. * Event resulting in death.